Skip to content
Research/Peptides/IGF-1 LR3

IGF-1 LR3

IGF-1 Long R3 variant. 83-amino acid analog of IGF-1. Long-acting insulin-like growth factor with higher potency. Muscle growth, anabolism, fat loss, recovery.

Intelligence Profile

Science

Mechanism of Action

IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a synthetic analog of natural insulin-like growth factor-1 (IGF-1) that has been modified to enhance its biological activity and duration of action.

Molecular Structure and Properties

IGF-1 LR3 differs from native IGF-1 through two key modifications: an N-terminal extension of 13 amino acids and a substitution of arginine for glutamic acid at position 3. These structural changes significantly reduce the peptide's binding affinity to IGF-binding proteins (IGFBPs), which normally regulate and limit IGF-1 activity in tissues.

Cellular Signaling Mechanisms

Like native IGF-1, IGF-1 LR3 exerts its effects primarily through activation of the IGF-1 receptor (IGF-1R), a transmembrane tyrosine kinase receptor. Upon binding to IGF-1R, the compound triggers downstream signaling cascades including:

  • PI3K/Akt pathway: Promotes cell survival, protein synthesis, and glucose uptake
  • MAPK/ERK pathway: Stimulates cell proliferation and differentiation
  • mTOR signaling: Enhances protein synthesis and muscle growth

Physiological Effects

Research indicates IGF-1 LR3 demonstrates activity across multiple tissue types:

Muscle and Regenerative Medicine: Studies have investigated IGF-1 LR3 in muscle void fillers for volumetric muscle loss treatment and in nerve regeneration applications using controlled-release delivery systems.

Metabolic Effects: Research in fetal sheep models has examined IGF-1 LR3's impact on glucose-stimulated insulin secretion, though findings suggest acute infusion effects may not persist in isolated pancreatic islets.

Neurological Applications: Intranasal administration studies in mouse models of Alzheimer's disease have shown IGF-1 LR3 can promote amyloid plaque remodeling in cerebral cortex, though cognitive preservation was not demonstrated in these studies.

Enhanced Pharmacokinetics

The structural modifications in IGF-1 LR3 result in reduced binding to IGFBPs, potentially leading to:

  • Extended half-life compared to native IGF-1
  • Enhanced bioavailability in target tissues
  • More sustained receptor activation

Limitations in Current Evidence

It's important to note that while these mechanisms are supported by research findings, the clinical evidence base for IGF-1 LR3 remains limited. Some studies, such as those in growth-restricted fetal sheep, have shown that IGF-1 LR3 does not consistently promote growth in all physiological contexts, highlighting the complexity of IGF-1 signaling and the need for further research to fully characterize this compound's therapeutic potential.

This information is for educational purposes only and should not be considered medical advice. Consult healthcare professionals for guidance on any medical treatments.